Lynch Syndrome Clinical Trial
Official title:
HEALTH4Families: Optimizing a Weight Management and Health Behavior Intervention for BRCA+ and Lynch Syndrome Families
Verified date | May 2024 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies how well weight management and health behavior intervention works in helping patients with hereditary breast and ovarian cancer and Lynch syndrome mutation carriers lose or maintain a healthy weight and lower their risk for cancer. Lifestyle behaviors such as physical activity, diet, and weight management may play a key role in preventing cancers and improving outcomes even in those with hereditary cancer syndromes.
Status | Active, not recruiting |
Enrollment | 384 |
Est. completion date | April 30, 2026 |
Est. primary completion date | April 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - HEALTH4Families only: Positive for either HBOC or LS predisposing mutations OR a family member of a mutation carrier (family members do not need to be biological relatives). - HEALTH4Families only: Index participant ONLY: Must have at least one family member who is eligible and consents to participation. - Have at least one of the following risk factors: - Body mass index (BMI) of 25 or higher - < 5 servings of vegetables and fruits per day - < 150 minutes per week of moderate intensity activity - 75 minutes per week of vigorous intensity activity - Able to read and write English. - Have a cellular telephone and are able and willing to send and receive text messages. - Access to internet via desktop or mobile device. - Capable of participating in moderate-vigorous unsupervised exercise. - HEALTH4CPC only: Patient in MD Anderson's Cancer Prevention Center coming in to the clinic for one of the following appointment types: consult and new patient screening appointments - HEALTH4CPC only: Female. - HEALTH4CPC only: Lives in the Houston area or surrounding counties (within 150 miles of MD Anderson's main campus). - HEALTH4CPC only: Has a smartphone. Exclusion Criteria: - Unable to walk without crutches, walker, cane, or other assistive device. - Women who are pregnant or nursing (by self-report). - Currently receiving radiation therapy or cytotoxic chemotherapy. - Within 3 months of major surgery. - Does not live in the United States. - HEALTH4CPC only: Persons diagnosed with any invasive cancer excluding non-melanoma skin cancer. - HEALTH4CPC only: Patient at high risk for cancer. - HEALTH4CPC only: Participated in the HEALTH 4 MD Anderson pilot study (protocol 2014-0230). |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent weight loss | The data from the proposed factorial experiment will be analyzed through analysis of variance (ANOVA) with repeated measures. The outcome variable is the percent weight loss of each participant at 4 months. The fixed covariates include indicator variables for all intervention components. The model includes a random intercept that introduces within-family correlation. The main effect of each intervention component will be tested in an F-test at alpha = 0.0125 level. The pairwise interactions of the intervention components will be studied in an exploratory fashion. The optimal intervention is defined to be the combination of the four components that produces the best percent weight loss result within the resource constraints. Data can also be analyzed jointly in a linear mixed model that includes intervention components and time as fixed effect, family as random intercept and longitudinal correlation between 4 and 8 month data. | Baseline to 4 months | |
Secondary | Fruit and vegetable consumption | The data from the proposed factorial experiment will be analyzed through ANOVA with repeated measures. The fixed covariates include indicator variables for all intervention components. The model includes a random intercept that introduces within-family correlation. The main effect of each intervention component will be tested in an F-test at alpha = 0.0125 level. Similar ANOVA analysis will be conducted for the 8 month outcome to study whether the intervention effect persists 4 months after the end of the intervention. The 4- and 8-month data can also be analyzed jointly in a linear mixed model that includes intervention components and time as fixed effect, family as random intercept and longitudinal correlation between 4 and 8 month data. | Up to 8 months | |
Secondary | Percent energy from fat | The data from the proposed factorial experiment will be analyzed through ANOVA with repeated measures. The fixed covariates include indicator variables for all intervention components. The model includes a random intercept that introduces within-family correlation. The main effect of each intervention component will be tested in an F-test at alpha = 0.0125 level. Similar ANOVA analysis will be conducted for the 8 month outcome to study whether the intervention effect persists 4 months after the end of the intervention. The 4- and 8-month data can also be analyzed jointly in a linear mixed model that includes intervention components and time as fixed effect, family as random intercept and longitudinal correlation between 4 and 8 month data. | Up to 8 months | |
Secondary | Physical activity | The data from the proposed factorial experiment will be analyzed through ANOVA with repeated measures. The fixed covariates include indicator variables for all intervention components. The model includes a random intercept that introduces within-family correlation. The main effect of each intervention component will be tested in an F-test at alpha = 0.0125 level. Similar ANOVA analysis will be conducted for the 8 month outcome to study whether the intervention effect persists 4 months after the end of the intervention. The 4- and 8-month data can also be analyzed jointly in a linear mixed model that includes intervention components and time as fixed effect, family as random intercept and longitudinal correlation between 4 and 8 month data. | Up to 8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00217737 -
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
|
Phase 3 | |
Completed |
NCT00905710 -
Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Recruiting |
NCT04909671 -
Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.
|
N/A | |
Recruiting |
NCT04379999 -
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
|
Early Phase 1 | |
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Completed |
NCT01845753 -
Molecular Screening for Lynch Syndrome in Denmark
|
||
Completed |
NCT01216930 -
Molecular Screening for Lynch Syndrome in Southern Denmark
|
N/A | |
Not yet recruiting |
NCT05963191 -
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02912559 -
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
|
Phase 3 | |
Recruiting |
NCT04978350 -
Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study
|
N/A | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Withdrawn |
NCT04778566 -
Evaluating the Cologuard Test for Use in Lynch Syndrome
|
||
Completed |
NCT02570516 -
NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome
|
N/A | |
Completed |
NCT01823471 -
I-Scan For Colon Polyp Detection In HNPCC
|
N/A | |
Recruiting |
NCT02813824 -
Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
|
Phase 3 | |
Recruiting |
NCT05078866 -
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT03744962 -
MSI in Circulatory DNA of Endometrial Cancer
|
||
Recruiting |
NCT04711434 -
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
|
Phase 3 | |
Completed |
NCT04131062 -
Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants
|
N/A |